Apollon Formularies (AQSE:APOL) FCF Margin % : -64.58% (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Apollon Formularies's Free Cash Flow for the six months ended in Jun. 2023 was £-0.03 Mil. Apollon Formularies's Revenue for the six months ended in Jun. 2023 was £0.05 Mil. Therefore, Apollon Formularies's FCF Margin % for the quarter that ended in Jun. 2023 was -64.58%.

As of today, Apollon Formularies's current FCF Yield % is -2.76%.

The historical rank and industry rank for Apollon Formularies's FCF Margin % or its related term are showing as below:

AQSE:APOL' s FCF Margin % Range Over the Past 10 Years
Min: -36133.33 Med: -823.73 Max: -0.96
Current: -64.58

During the past 11 years, the highest FCF Margin % of Apollon Formularies was -0.96%. The lowest was -36133.33%. And the median was -823.73%.

AQSE:APOL's FCF Margin % is ranked worse than
86.76% of 1027 companies
in the Drug Manufacturers industry
Industry Median: -0.12 vs AQSE:APOL: -64.58

Apollon Formularies FCF Margin % Historical Data

The historical data trend for Apollon Formularies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies FCF Margin % Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

-0.96

-17.80

-1,568.69

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
FCF Margin %	Get a 7-Day Free Trial											-	-	-1,092.93	-130.30	-64.58

Competitive Comparison of Apollon Formularies's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's FCF Margin % falls into.

Apollon Formularies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Apollon Formularies's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-3.106	/	0.198
	=	-1,568.69 %

Apollon Formularies's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-0.031	/	0.048
	=	-64.58 %

Apollon Formularies FCF Margin % Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.